Drug Profile
XR 3005
Latest Information Update: 01 Aug 2002
Price :
$50
*
At a glance
- Originator Xenova Group
- Class Antineoplastics
- Mechanism of Action Farnesyltranstransferase inhibitors; Ras protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Cancer
Most Recent Events
- 01 Aug 2002 Discontinued - Preclinical for Cancer in United Kingdom (unspecified route)
- 16 Jul 1998 Profile reviewed
- 16 Jul 1998 No-Development-Reported for Cancer in United Kingdom (Unknown route)